SynAct Pharma
10,9
SEK
-0,18 %
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 investorer følger denne virksomhed
-0,18%
+36,25%
+29,45%
+55,71%
+23,44%
+35,24%
-91,89%
+28,23%
+134,33%
synactpharma.com/en
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and various joint injuries. The subsidiary SynAct Pharma Aps was initially founded in 2012 and the parent company was established in 2016. The head office is located in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
SYNACT
Daglig lav / høj pris
10,5 / 11,33
SEK
Markedsværdi
450,13 mio. SEK
Aktieomsætning
1,12 mio. SEK
Volumen
103 t
Seneste videoer
Finanskalender
Ekstraordinær generalforsamling
13.12.2024
Årsrapport
18.02.2025
Generalforsamling
27.05.2025
Delårsrapport
27.05.2025
Delårsrapport
20.08.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Sanos Group NBCD | 9,6 % | 9,6 % |
| Avanza Pension | 6,8 % | 6,8 % |
| Thomas Jonassen | 6,2 % | 6,2 % |
| Thomas Ringberg | 5,5 % | 5,5 % |
| Nordnet Pensionsförsäkring | 4,6 % | 4,6 % |
| Thomas von Koch | 2,7 % | 2,7 % |
| Handelsbanken Fonder | 1,9 % | 1,9 % |
| Torbjörn Bjerke | 1,9 % | 1,9 % |
| Kenneth Bjerg-Nielsen | 1,6 % | 1,6 % |
| OR Invest A/S | 1,0 % | 1,0 % |
ViserAlle indholdstyper
Nomination committee appointed ahead of AGM 2025 in SynAct Pharma AB
BioStock: New and larger shareholders back SynAct's capital raise - CEO comments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
Notice of extraordinary general meeting in SynAct Pharma AB
SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
SynAct Pharma publishes Q3 2024 interim results
SynAct Pharma to attend BIO-Europe in Stockholm November 4-6
SynAct Pharma's Chairman to BioStock: "We are confident we have the right strategy"
